Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 7/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30722468 | 0.95 | FOLH1 (0.51) | FOLH1GNPATBACE1CTSDPTPN1 | |
| SCHEMBL29883820 | 0.95 | BMP1 (0.46) | FOLH1BACE1CTSDPTPN1MME | |
| SCHEMBL29679903 | 0.93 | FOLH1 (0.55) | FOLH1BACE1CTSDPTPN1BMP1 | |
| SCHEMBL30808892 | 0.93 | BACE1 (0.48) | FOLH1BACE1CTSDNOD1 | |
| SCHEMBL31751397 | 0.93 | PTPN1 (0.54) | FOLH1BACE1CTSDPTPN1 | |
| SCHEMBL30261690 | 0.92 | FOLH1 (0.51) | FOLH1GNPATBACE1CTSDBACE2 | |
| SCHEMBL30903465 | 0.92 | FOLH1 (0.49) | FOLH1BACE1CTSDBMP1NOD1 | |
| SCHEMBL4221701 | 0.92 | FOLH1 (0.51) | FOLH1MMENOD1 | |
| SCHEMBL4221705 | 0.92 | FOLH1 (0.51) | FOLH1MMENOD1 | |
| SCHEMBL29679534 | 0.91 | FOLH1 (0.56) | FOLH1BACE1CTSDPTPN1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701647-A1 | PEPTIDES WITH MULTIVALENT EFFECTS FOR TOPICAL USE | In2Cure AB (SE) | 2026-03-04 | — | — | EP | claimed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2024223868-A1 | PEPTIDES WITH MULTIVALENT EFFECTS FOR TOPICAL USE | IN2CURE AB (SE) | 2024-10-31 | — | — | WO | claimed |
| CN-118747003-A | Water surface unmanned ship mixed path planning method considering underwater obstacle | 广东工业大学 | 2024-10-08 | — | — | CN | claimed |
| EP-4419664-A1 | PEPTIDES WITH MULTIVALENT EFFECTS | In2Cure AB (SE) | 2024-08-28 | — | — | EP | claimed |
| WO-2023067167-A1 | PEPTIDES WITH MULTIVALENT EFFECTS | IN2CURE AB (SE) | 2023-04-27 | — | — | WO | claimed |
| US-20230119640-A1 | ANTIBACTERIAL HYDROPHILIC COMPOUND | SHENZHEN UNIVERSITY (CN) | 2023-04-20 | — | — | US | claimed |
| US-11503828-B2 | Antibacterial hydrophilic compound and use thereof | SHENZHEN UNIVERSITY (CN) | 2022-11-22 | — | — | US | claimed |
| EP-4701647-A1 | PEPTIDES WITH MULTIVALENT EFFECTS FOR TOPICAL USE | In2Cure AB (SE) | 2026-03-04 | — | — | EP | disclosed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | disclosed |
| US-12473332-B2 | Modified peptides and associated methods of use | ADVANCED TECH FOR NOVEL THERAPEUTICS LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250034545-A1 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY | KAI PHARMACEUTICALS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024223868-A1 | PEPTIDES WITH MULTIVALENT EFFECTS FOR TOPICAL USE | IN2CURE AB (SE) | 2024-10-31 | — | — | WO | disclosed |
| EP-4419664-A1 | PEPTIDES WITH MULTIVALENT EFFECTS | In2Cure AB (SE) | 2024-08-28 | — | — | EP | disclosed |
| US-11820837-B2 | Modified peptides and associated methods of use | ADVANCED TECHNOLOGIES FOR NOVEL THERAPEUTICS, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023067167-A1 | PEPTIDES WITH MULTIVALENT EFFECTS | IN2CURE AB (SE) | 2023-04-27 | — | — | WO | disclosed |
| US-20230119640-A1 | ANTIBACTERIAL HYDROPHILIC COMPOUND | SHENZHEN UNIVERSITY (CN) | 2023-04-20 | — | — | US | disclosed |
| US-11503828-B2 | Antibacterial hydrophilic compound and use thereof | SHENZHEN UNIVERSITY (CN) | 2022-11-22 | — | — | US | disclosed |
| US-20220282239-A1 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY | KAI PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-110092737-B | Antistatic compound, surface treatment method of material and modified material | 海思美域(深圳)科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11503828-B2 | Antibacterial hydrophilic compound and use thereof | HIRA, NOD2, HIRIP3 | FOLH1 3970/4885GNPAT 3230/4885BACE1 4040/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | FOLH1 479/4885GNPAT 4167/4885BACE1 1727/4885 |
| US-20230119640-A1 | ANTIBACTERIAL HYDROPHILIC COMPOUND | HIRA, NOD2, CHLSN | FOLH1 4093/4885GNPAT 2727/4885BACE1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.